Industry News
Biotechnology Industry News
Ready to eat: Investors fork out $76M for Pheast’s cancer therapies
Ready to eat: Investors fork out $76M for Pheast's cancer therapies gmasson Mon, 04/25/2022 - 18:59
Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends
Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends aarmstrong Mon, 04/25/2022 - 17:22
UPDATE: Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends
UPDATE: Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends aarmstrong Mon, 04/25/2022 - 17:22
Trevena’s COVID-19 drug trial halted for inferiority, as NIH continues ACTIV house cleaning
Trevena's COVID-19 drug trial halted for inferiority, as NIH continues ACTIV house cleaning mbayer Mon, 04/25/2022 - 15:53
UPDATE: Trevena’s COVID-19 drug trial halted for inferiority as NIH continues ACTIV house cleaning
UPDATE: Trevena's COVID-19 drug trial halted for inferiority as NIH continues ACTIV house cleaning mbayer Mon, 04/25/2022 - 15:53
Progress with Promise with Ibex® Design’s 11-month DNA to IND guarantee
Progress with Promise with Ibex® Design’s 11-month DNA to IND guarantee ncavazza Mon, 04/25/2022 - 15:26
Another setback for Axsome as migraine med expected to get a no from FDA
Another setback for Axsome as migraine med expected to get a no from FDA mbayer Mon, 04/25/2022 - 13:33
Vivo Capital seeds new venture with $60M to take Arrowhead therapies to China
Vivo Capital seeds new venture with $60M to take Arrowhead therapies to China aarmstrong Mon, 04/25/2022 - 12:29
Roche delays DMD drug deadline, decides to rejig MS trials because of Ukraine war
Roche delays DMD drug deadline, decides to rejig MS trials because of Ukraine war jwaldron Mon, 04/25/2022 - 10:45
Black Diamond runs into rocky terrain, trims 30% of workforce and cuts precision oncology program
Black Diamond runs into rocky terrain, trims 30% of workforce and cuts precision oncology program aarmstrong Mon, 04/25/2022 - 10:40
UPDATE: Nkarta touts a double dose of data for natural killer cell therapies
UPDATE: Nkarta touts a double dose of data for natural killer cell therapies gmasson Mon, 04/25/2022 - 10:35
Phase 2 deja vu for gossamer bio after ulcerative colitis med flops
Phase 2 deja vu for gossamer bio after ulcerative colitis med flops mbayer Mon, 04/25/2022 - 10:27
Weeks after Sanofi flop, Roche’s rival breast cancer drug flunks phase 2 test
Weeks after Sanofi flop, Roche's rival breast cancer drug flunks phase 2 test ntaylor Mon, 04/25/2022 - 03:55
Agilex Biolabs Doubles in Size with Launch of New Large Molecule Facility as It Expands Its U.S. Presence
Agilex Biolabs Doubles in Size with Launch of New Large Molecule Facility as It Expands Its U.S. Presence mwen Fri, 04/22/2022 - 13:41
Vallon looks for escape route a month after sole clinical asset fails in clinic
Vallon looks for escape route a month after sole clinical asset fails in clinic mbayer Fri, 04/22/2022 - 10:55
Astellas takes $170M hit as DMD gene therapy plan unravels in wake of preclinical data
Astellas takes $170M hit as DMD gene therapy plan unravels in wake of preclinical data ntaylor Fri, 04/22/2022 - 07:47
The Clever-1? Faron hails melanoma data despite lack of responses
The Clever-1? Faron hails melanoma data despite lack of responses ntaylor Fri, 04/22/2022 - 05:26
Chutes & Ladders—Romanelli returns to Merck to lead international human health team after brief CEO stint
Chutes & Ladders—Romanelli returns to Merck to lead international human health team after brief CEO stint mbayer Thu, 04/21/2022 - 17:51
Bayer nabs yet another oncology leader from GSK to bolster cancer efforts
Bayer nabs yet another oncology leader from GSK to bolster cancer efforts gmasson Thu, 04/21/2022 - 15:45
Novavax executives’ pay comes back down to Earth after 8-figure package in 2020
Novavax executives' pay comes back down to Earth after 8-figure package in 2020 aarmstrong Thu, 04/21/2022 - 14:41